We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Technology Identifies Viral RNA Mutations in Clinical Samples

By LabMedica International staff writers
Posted on 09 Nov 2015
Print article
The QX200 AutoDG Droplet Digital polymerase chain reaction (ddPCR) dystem
The QX200 AutoDG Droplet Digital polymerase chain reaction (ddPCR) dystem (Photo courtesy of BIO-RAD LABORATORIES)
Droplet Digital polymerase chain reaction (ddPCR) uses emulsion chemistry to partition nucleic acid samples into approximately 20,000 oil-encapsulated nanodroplets to produce data that surpasses the precision of other molecular methods with equivalent or much higher sensitivity.

Numerous circumstances can lead to a weakened immune system, making the body more susceptible to viral infection and knowing whether the infection is developing resistance to certain drugs is key to providing optimal treatment, as such resistance can often develop from a single, spontaneous point mutation in the viral ribonucleic acid (RNA).

Scientists at Central University Hospital and Laval University (Quebec City, QC, Canada) working with their colleagues compared the percent mutation abundance between ddPCR and reverse transcription quantitative PCR (RT-qPCR) platforms, on nucleic acid extracts of patient samples were collected over time. Influenza A (H1N1) pdm09 virus infection was diagnosed on January 5, 2011, in a 31 month-old boy with medulloblastoma who received consolidation chemotherapy in preparation of an autologous bone marrow transplantation.

The amplification process for the RT-qPCR was performed in a LightCycler 480 real-time thermocycler (Roche Applied Science, Mannheim, Germany). For all reactions split between RT-qPCR and ddPCR, the amplification process was performed in a LightCycler 480 real-time thermocycler using the optimized ddPCR cycling protocol. For the ddPCR 20 µL of each reaction mix was converted to droplets with the QX200 droplet generator (Bio-Rad; Hercules, CA, USA). Droplet-partitioned samples were then transferred to a 96-well plate, sealed and cycled in a Bio-Rad C1000 deep well Thermocycler.

The scientists used a mixture of mutant and wild-type viral RNA to show that ddPCR technology markedly increased the sensitivity by more than 30-fold and precision by more than 10-fold, for both inter- and intra-assay variability of mutation abundance quantification when compared to RT-qPCR. Because ddPCR is based on absolute quantification, it can remove much of the variability intrinsic to RT-qPCR, which relies on relative quantification. The investigators discovered a statistically significant correlation between two independent ddPCR datasets that was not found with RT-qPCR, allowing for accurate identification of a residual mutant viral population.

Guy Boivin, MD, MSc, FRCPC, an associate professor of microbiology and senior author of the study said, “Influenza research, especially translational research, needs rapid and reproducible methods. We plan to use Droplet Digital PCR to follow the fate of immunocompromised patients on antiviral therapy.” The study was published in the November 2015 issue of the Journal of Virological Methods.

Related Links:

Central University Hospital and Laval University
Roche Applied Science 
Bio-Rad Laboratories 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.